Skip to main content

Table 4 Multiple comparison test of HDL-C level among treatment duration periods, by sex.

From: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records

Treatment duration Female HDL-C (nmol/L) Male HDL-C (nmol/L)
  Exam.N LS mean ± SE 95% CI p value Exam.N LS mean ± SE 95% CI p value
Baseline 102 1.57 ± 0.04 1.50/1.65 reference 210 1.38 ± 0.04 1.33/1.44 reference
0~3M 53 1.51 ± 0.04 1.42/1.59 0.1087 84 1.40 ± 0.03 1.34/1.47 0.889
3~6M 41 1.56 ± 0.04 1.47/1.64 0.9579 73 1.36 ± 0.03 1.29/1.42 0.8245
6~9M 26 1.45 ± 0.05 1.36/1.55 0.0054* 58 1.37 ± 0.04 1.30/1.44 0.9719
9~12M 15 1.47 ± 0.06 1.36/1.59 0.1423 46 1.36 ± 0.04 1.28/1.44 0.9444
  1. HDL-C: high density lipoprotein cholesterol, Exam N: number of examinations, LS mean: least squares mean, SE: standard error, CI: confidence interval, p value: p value of treatment duration period (compared with baseline, multiple-comparison test: Dunnett-Hsu post-hoc analysis), *: p < 0.05.